177 related articles for article (PubMed ID: 27165496)
1. Biological Therapy-Induced Systemic Vasculitis.
Gutiérrez-González LA
Curr Rheumatol Rep; 2016 Jul; 18(7):39. PubMed ID: 27165496
[TBL] [Abstract][Full Text] [Related]
2. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort.
Piga M; Chessa E; Ibba V; Mura V; Floris A; Cauli A; Mathieu A
Autoimmun Rev; 2014 Aug; 13(8):873-9. PubMed ID: 24840285
[TBL] [Abstract][Full Text] [Related]
3. Comparative overview of safety of the biologics in rheumatoid arthritis.
Khraishi M
J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
5. Ulcerative keratitis in patients with rheumatoid arthritis in the modern biologic era: a series of eight cases and literature review.
Watanabe R; Ishii T; Yoshida M; Takada N; Yokokura S; Shirota Y; Fujii H; Harigae H
Int J Rheum Dis; 2017 Feb; 20(2):225-230. PubMed ID: 26179634
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.
Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X;
Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726
[TBL] [Abstract][Full Text] [Related]
7. [Safety of biologic therapy - results from the German biologics register RABBIT].
Strangfeld A; Zink A
Dtsch Med Wochenschr; 2014 Sep; 139(37):1817-20. PubMed ID: 25180996
[No Abstract] [Full Text] [Related]
8. Safety of Biologic Agents in Elderly Patients with Rheumatoid Arthritis.
Murota A; Kaneko Y; Yamaoka K; Takeuchi T
J Rheumatol; 2016 Nov; 43(11):1984-1988. PubMed ID: 27585685
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab in rheumatic diseases.
Rath E; Zwerina J; Oppl B; Nell-Duxneuner V
Wien Med Wochenschr; 2015 Jan; 165(1-2):28-35. PubMed ID: 25676699
[TBL] [Abstract][Full Text] [Related]
10. The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis.
Ruderman EM
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S29-32. PubMed ID: 24219038
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
Siddiqui MA
Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
[TBL] [Abstract][Full Text] [Related]
12. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study.
Lang HC; Lee HC; Lee SS; Lin HY; Chiu YM
Int J Rheum Dis; 2016 Nov; 19(11):1112-1118. PubMed ID: 26890537
[TBL] [Abstract][Full Text] [Related]
13. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies.
Chen J; Chi S; Li F; Yang J; Cho WC; Liu X
Expert Opin Biol Ther; 2017 Mar; 17(3):265-283. PubMed ID: 28117616
[TBL] [Abstract][Full Text] [Related]
14. The British Society for Rheumatology Biologics Register: 6 years on.
Hyrich KL; Watson KD; Isenberg DA; Symmons DP;
Rheumatology (Oxford); 2008 Oct; 47(10):1441-3. PubMed ID: 18596052
[No Abstract] [Full Text] [Related]
15. Safety of disease-modifying antirheumatic drugs and biologic agents for rheumatoid arthritis patients in real-life conditions.
Abasolo L; Leon L; Rodriguez-Rodriguez L; Tobias A; Rosales Z; Maria Leal J; Castaño V; Vadillo C; Macarron P; Fontsere O; Jover JA
Semin Arthritis Rheum; 2015 Apr; 44(5):506-513. PubMed ID: 25532946
[TBL] [Abstract][Full Text] [Related]
16. Biological therapies for rheumatoid arthritis: progress to date.
Malviya G; Salemi S; Laganà B; Diamanti AP; D'Amelio R; Signore A
BioDrugs; 2013 Aug; 27(4):329-45. PubMed ID: 23558378
[TBL] [Abstract][Full Text] [Related]
17. Treatment of rheumatoid arthritis: Unraveling the conundrum.
Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
Müller RB; von Kempis J; Haile SR; Schiff MH
Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
20. A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice.
Nicholls D; Zochling J; Boers A; Champion G; Mathers D; Riordan J; Youssef P; Scott J; Griffiths H
Int J Rheum Dis; 2014 Sep; 17(7):755-61. PubMed ID: 24131467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
